相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dabigatran Etexilate A New Oral Thrombin Inhibitor
Graeme J. Hankey et al.
CIRCULATION (2011)
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
Thomas Mavrakanas et al.
PHARMACOLOGY & THERAPEUTICS (2011)
Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands
Narayanam V. Rao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2010)
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT)
L. Rauova et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Rivaroxaban - an oral, direct Factor Xa inhibitor - has potential for the management of patients with heparin-induced thrombocytopenia
Jeanine M. Walenga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Heparin-induced thrombocytopenia - therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes
K. Krauel et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Heparin-induced thrombocytopenia
Theodore E. Warkentin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
PF-4/CXCL4 and CXCLAL1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion
Laura Lasagni et al.
BLOOD (2007)
Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies
Andreas Greinacher et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Heparin-induced thrombocytopenia
Gowthami M. Arepally et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia
D Juhl et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications
L Rauova et al.
BLOOD (2006)
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
D Kubitza et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Regulated expression of platelet factor 4 in human monocytes - role of PARs as a quantitatively important monocyte activation pathway
A Schaffner et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4
L Lasagni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins
LC Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcγRIIA
MP Reilly et al.
BLOOD (2001)
分享论文
